(dailyRx)

Researchers at Emory University recommend that progesterone, a naturally occurring hormone found in both males and females that can protect damaged cells in the central and peripheral nervous systems, should be considered a viable treatment option for traumatic brain injuries.
This recommendation comes from a clinical perspective published in the January issue of the American Journal of Roentgenology.

"Traumatic brain injury [TBI] is an important clinical problem in the United States and around the world," said Donald G. Stein, Ph.D., lead author of the paper. "TBI has received more attention recently because of its high incidence among combat casualties in Iraq and Afghanistan. Current Department of Defense statistics indicated that as many as 30 percent of wounded soldiers seen at Walter Reed Army Hospital have suffered a TBI, a finding that has stimulated government interest in developing a safe and effective treatment for this complex disorder," said Stein.

"Growing evidence indicates that post-injury administration of [progesterone] in a variety of brain damage models can have beneficial effects, leading to substantial and sustained improvements in brain functionality. [Progesterone] given to both males and females can cross the blood-brain barrier and reduce edema [swelling] levels after TBI; in different models of cerebral ischemia [restriction of blood supply], significantly reduce the area of necrotic cell death and improve behavioral outcomes; and protect neurons distal to the injury that would normally die," said Stein.

Progesterone was recently tested in two phase 2 clinical trials for traumatic brain injury and will begin a phase 3 trial sponsored by the National Institutes of Health soon.

"Given its relatively high safety profile, its ease of administration, its low cost and ready availability, [progesterone] should be considered a viable treatment option--especially because, in brain injury, so little else is currently available," said Stein.

Contact:
Heather Curry
703-390-9822
hcurry@acr-arrs.org